Novo Nordisk has launched the first GLP-1 weight-loss pill in the United States.
The once-daily Wegovy pill is the only oral GLP-1 treatment currently on the market.
It is priced far below injectable versions, accelerating competition across the sector.
Cash-paying patients can access the starting dose for $149 per month.
Higher doses will rise to between $199 and $299 monthly later this spring.
Patients with insurance may pay as little as $25 per month.
The pill is needle-free, potentially broadening appeal and improving adherence.
Novo aims to regain market share after intense rivalry with Eli Lilly.
The drug is available through major pharmacies including CVS and Costco.
Regulatory approval has so far been granted only in the United States.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.